Outcomes of pancreatic cancer with liver oligometastasis.
chemotherapy
liver metastasis
oligometastasis
pancreatic cancer
prognosis
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
29
03
2022
received:
02
02
2022
accepted:
05
04
2022
pubmed:
21
5
2022
medline:
17
2
2023
entrez:
20
5
2022
Statut:
ppublish
Résumé
Liver oligometastatic pancreatic cancer (PC) may have favorable outcomes. This study aims to evaluate outcomes and factors associated with overall survival (OS) of these patients. We retrospectively investigated consecutive PC patients with liver metastasis treated at our institution between 2013 and 2020. Clinical characteristics and outcomes were compared and analyzed according to the extent of liver metastasis. Cox proportional hazards model was used to identify prognostic factors for OS. A total of 417 patients were included (multi-organ metastasis/polymetastasis/oligometastasis 174/158/85). Oligometastasis showed a longer OS compared to other types of metastases (7.7 vs 8.2 vs 13.1 months). Age <70 years, performance status of 0, modified Glasgow prognostic score of 0, carbohydrate antigen 19-9 <1000 U/mL were identified as significant prognostic factors for OS. A prognostic index consisting of these four factors successfully stratified the prognosis of these patients (prognostic index; high vs low, 19.9 vs 8.3 months). Highly selected patients who underwent surgical resection showed a median OS of 54.6 months. Oligometastasis presented a relatively favorable outcome. Our new prognostic index was useful in stratifying the prognosis of these patients. Multimodal treatment including surgery may have additional survival benefits for highly selected patients.
Sections du résumé
BACKGROUND
BACKGROUND
Liver oligometastatic pancreatic cancer (PC) may have favorable outcomes. This study aims to evaluate outcomes and factors associated with overall survival (OS) of these patients.
METHODS
METHODS
We retrospectively investigated consecutive PC patients with liver metastasis treated at our institution between 2013 and 2020. Clinical characteristics and outcomes were compared and analyzed according to the extent of liver metastasis. Cox proportional hazards model was used to identify prognostic factors for OS.
RESULTS
RESULTS
A total of 417 patients were included (multi-organ metastasis/polymetastasis/oligometastasis 174/158/85). Oligometastasis showed a longer OS compared to other types of metastases (7.7 vs 8.2 vs 13.1 months). Age <70 years, performance status of 0, modified Glasgow prognostic score of 0, carbohydrate antigen 19-9 <1000 U/mL were identified as significant prognostic factors for OS. A prognostic index consisting of these four factors successfully stratified the prognosis of these patients (prognostic index; high vs low, 19.9 vs 8.3 months). Highly selected patients who underwent surgical resection showed a median OS of 54.6 months.
CONCLUSIONS
CONCLUSIONS
Oligometastasis presented a relatively favorable outcome. Our new prognostic index was useful in stratifying the prognosis of these patients. Multimodal treatment including surgery may have additional survival benefits for highly selected patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-239Informations de copyright
© 2022 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Références
Szturz P, Vermorken JB. Oligometastatic cancer: key concepts and research opportunities for 2021 and beyond. Cancers (Basel). 2021;13:2518.
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10.
Chandy ETJ, Saxby HJ, Pang JW, Sharma RA. The multidisciplinary management of oligometastases from colorectal cancer: a narrative review. Ann Palliat Med. 2021;10:5988-6001.
Salati M, Valeri N, Spallanzani A, Braconi C, Cascinu S. Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications. Eur J Surg Oncol. 2019;45:1479-82.
Kwapisz D. Oligometastatic breast cancer. Breast Cancer. 2019;26:138-46.
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15-25.
Juan O, Popat S. Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 2017;18:595-606.
Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical management of neuroendocrine tumor liver metastases. Surg Oncol Clin N Am. 2021;30:39-55.
Kandel P, Wallace MB, Stauffer J, Bolan C, Raimondo M, Woodward TA, et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer. 2018;4:88-94.
Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, et al. Downstaging in stage iv pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24:2397-403.
Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533-9.
Tanaka M, Heckler M, Mihaljevic AL, Sun H, Klaiber U, Heger U, et al. Ct response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after folfirinox. Eur J Surg Oncol. 2019;45:1453-9.
Wright GP, Poruk KE, Zenati MS, Steve J, Bahary N, Hogg ME, et al. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg. 2016;20:1830-5.
Damanakis AI, Ostertag L, Waldschmidt D, Kutting F, Quaas A, Plum P, et al. Proposal for a definition of "oligometastatic disease in pancreatic cancer". BMC Cancer. 2019;19:1261.
Yamanaka M, Hayashi M, Yamada S, Sonohara F, Takami H, Inokawa Y, et al. A possible definition of oligometastasis in pancreatic cancer and associated survival outcomes. Anticancer Res. 2021;41:3933-40.
Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, et al. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology. 2021;21:903-11.
Wei M, Shi S, Hua J, Xu J, Yu X. Chinese study Group for Pancreatic C: simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (cspac-1). BMJ Open. 2019;9:e033452.
Oba A, Inoue Y, Ono Y, Irie S, Sato T, Mise Y, et al. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Langenbecks Arch Surg. 2020;405:35-41.
Oba A, Inoue Y, Ono Y, Ishizuka N, Arakaki M, Sato T, et al. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the sling trial. Br J Surg. 2021;108:115-8.
Imaoka H, Mizuno N, Hara K, Hijioka S, Tajika M, Tanaka T, et al. Evaluation of modified Glasgow prognostic score for pancreatic cancer: a retrospective cohort study. Pancreas. 2016;45:211-7.
Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181-9.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The clavien-dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187-96.
Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-9.
Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, et al. Modified folfirinox as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer. 2020;20:449.
Kanda Y. Investigation of the freely available easy-to-use software 'ezr' for medical statistics. Bone Marrow Transplant. 2013;48:452-8.
Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: a review of current literature. Pancreatology. 2019;19:672-80.
Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, de Vries JJJ, et al. Locoregional treatment of metastatic pancreatic cancer utilizing resection, ablation and embolization: a systematic review. Cancers (Basel). 2021;13:1608.
Yokoyama N, Otani T, Hashidate H, Maeda C, Katada T, Sudo N, et al. Real-time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging: preliminary results of a prospective study. Cancer. 2012;118:2813-9.
Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2-11.
Hua YQ, Wang P, Zhu XY, Shen YH, Wang K, Shi WD, et al. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: an analysis of safety and efficacy. Pancreatology. 2017;17:967-73.